Published in Blood Weekly, July 17th, 2003
DLI "is recognized as effective therapy for relapse after stem cell transplantation" in CML patients, researchers in Japan explained. "However, the clinical efficacy of DLI in the advanced phase of CML or other types of leukemia has not been clearly defined because of its varying degree of success."
K. Matsue and colleagues at Kameda General Hospital in Chiba described the case of a "22-year-old male patient with promyelocytic crisis of CML who had a relapse after peripheral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.